The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
NeoGenomics Inc has introduced PanTracer Pro, a new molecular testing solution designed to help clinicians make more informed treatment decisions for patients with advanced-stage solid tumors.
The test integrates genomic profiling with diagnosis-directed immunohistochemistry and ancillary testing selected based on tumor type. By delivering insights through a single coordinated order, PanTracer Pro enables physicians to assess relevant biomarkers upfront rather than through multiple, sequential tests.
“Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment,” says Tony Zook, chief executive officer at NeoGenomics, in a release. “PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey.”
Addressing Testing Workflow Challenges
The new test aims to address growing challenges in precision oncology, where clinicians face increasing diagnostic complexity, expanding biomarker requirements, and pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points.
PanTracer Pro combines DNA and RNA sequencing across more than 500 cancer-related genes with tumor-specific ancillary testing. The test has a turnaround time of eight to 10 days and supports therapy selection, helps identify potential clinical trial options, and facilitates personalized treatment planning based on a patient’s unique tumor biology.
Automatic Reflex Testing Option
When tissue samples are insufficient or unavailable, cases can automatically reflex to PanTracer LBx, NeoGenomics’ pan-solid tumor liquid biopsy assay. This feature allows clinicians to continue diagnostic workup without restarting the process.
The test may help identify clinically relevant biomarkers that can be missed with incomplete testing, according to the company. PanTracer Pro is now available as part of the PanTracer family of testing solutions.
ID 5635958 © Niderlander | Dreamstime.com
